Welcome to our dedicated page for AETHLON MEDICAL news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on AETHLON MEDICAL stock.
Aethlon Medical Inc. (Nasdaq: AEMD) is an innovative medical technology company dedicated to addressing unmet medical needs in health and biodefense. The company's core focus is on developing the Hemopurifier®, a clinical-stage therapeutic device designed to combat cancer and life-threatening viral infections, and for use in organ transplantation. Aethlon’s proprietary technology, the Aethlon ADAPT™ platform, provides the foundation for a new class of therapeutics that target the selective removal of disease-enabling particles from the entire circulatory system.
The Hemopurifier®, designated as a breakthrough device by the FDA, has demonstrated broad-spectrum capabilities against exosomes that contribute to the progression of cancer and viruses like HIV and Hepatitis C. Recent developments include ongoing research and clinical trials to evaluate the device's safety and efficacy in removing harmful exosomes and viruses from blood. These trials are taking place in India and Australia, targeting patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
Financially, Aethlon Medical reported a cash balance of approximately $8.0 million as of the end of 2023. The company also announced a public offering expected to raise around $4.7 million to support its clinical trials, research, and other corporate needs. The company's leadership, including Interim CEO and CFO Jim Frakes, is committed to advancing the Hemopurifier® and exploring new applications in oncology and infectious diseases.
Partnerships are a crucial aspect of Aethlon’s strategy. The company recently entered into a Materials Transfer Agreement with Santersus AG to explore potential synergies between the Hemopurifier® and Santersus' NucleoCapture devices for the treatment of cancer and organ transplantation. This collaboration aims to enhance the effectiveness of both technologies by combining their capabilities to remove specific harmful agents from the blood.
Overall, Aethlon Medical Inc. is at the forefront of developing groundbreaking medical devices aimed at improving outcomes for patients with severe health conditions, making significant strides in the fields of cancer and infectious diseases.
For more information, visit Aethlon Medical.
Aethlon Medical (NASDAQ: AEMD) reported its financial results for the third quarter ending December 31, 2022. The company continues developing the Hemopurifier®, focusing on cancer and life-threatening infectious diseases. A significant update includes a new oncology study set to initiate in Australia and the U.S. The company's cash balance stands at approximately $17.5 million, while operating expenses rose by 12% to roughly $2.85 million. Aethlon experienced a net loss of approximately $2.85 million, up from $2.53 million during the same period in 2021. The company did not record government contract revenue this quarter, impacting its financial results.
Aethlon Medical, Inc. (NASDAQ: AEMD) announced it will release its financial results for Q3 ended December 31, 2022, on February 6, 2023, at 4:15 p.m. EST. Following the results, a conference call will take place at 4:30 p.m. EST for management to discuss financial outcomes and corporate developments. The company focuses on developing the Hemopurifier, a clinical-stage device aimed at treating cancer and life-threatening infectious diseases. The Hemopurifier has received FDA Breakthrough Device designation due to its potential to remove harmful viruses and exosomes from blood.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced its virtual presentation scheduled for February 2nd, 2023, at 10:00 AM ET, during the Sequire Biotechnology Conference. Led by Steven LaRosa, M.D., the presentation will outline the company's innovative medical technology aimed at treating cancer and severe infectious diseases. The biotechnology industry is projected to reach $727 billion by 2025, featuring over 6,500 US companies. Aethlon's main technology, the Hemopurifier, has received FDA Breakthrough Device designation and targets advanced cancer and life-threatening viral infections.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced a strategic agreement with NAMSA, a leading MedTech Contract Research Organization, to oversee clinical trials for its Hemopurifier device targeting cancer treatments. The trials will begin in Australia and include patients with various cancer tumors. Aethlon aims to expedite the clinical development of the Hemopurifier, which has shown promise in removing harmful exosomes and viruses from blood. The device is designated by the FDA as a Breakthrough Device for advanced or metastatic cancer therapies. This partnership is expected to enhance the efficiency and effectiveness of Aethlon's clinical research efforts.
Aethlon Medical, Inc. (AEMD) reported financial results for Q2 2022, with a net loss of approximately $3.8 million, a significant increase from $2.0 million in Q2 2021. Operating expenses rose to $3.67 million, up 71% year-over-year. The company has terminated its U.S. COVID-19 trial and head and neck cancer safety trial due to low patient enrollment, reallocating funds to advance the Hemopurifier in oncology research. As of September 30, 2022, Aethlon had a cash balance of $19.6 million and plans to launch a new oncology trial while engaging a new CRO in the U.S. and Australia.
FAQ
What is the current stock price of AETHLON MEDICAL (AEMD)?
What is the market cap of AETHLON MEDICAL (AEMD)?
What is Aethlon Medical Inc.?
What is the Hemopurifier®?
What are the recent developments for Aethlon Medical?
Who is leading Aethlon Medical?
What are exosomes and why are they important?
How is Aethlon Medical funded?
What collaborations does Aethlon Medical have?
What makes the Hemopurifier® unique?
Where can I find more information about Aethlon Medical?
What are the financial highlights of Aethlon Medical?
